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results in vaccine-associated enhanced respiratory disease in weaned
piglets
Abstract
Control of influenza A virus (IAV) in pigs is done by vaccination of females to provide maternally-derived
antibodies (MDA) through colostrum. Our aim was to evaluate if MDA interfere with IAV infection, clinical
disease, and transmission in non-vaccinated piglets. In the first study, naïve sows were vaccinated with
H1N2-δ1 whole inactivated virus (WIV) vaccine. In a follow-up study seropositive sows to 2009 pandemic
H1N1 (H1N1pdm09) were boosted with H1N1pdm09 WIV or secondary experimental infection (EXP).
MDA-positive pigs were challenged with homologous or heterologous virus, and MDA-negative control
groups were included. WIV-MDA piglets were protected from homologous infection. However, piglets with
WIV-derived MDA subsequently challenged with heterologous virus developed vaccine associated enhanced
respiratory disease (VAERD), regardless of history of natural exposure in the sows. Our data indicates that
although high titers of vaccine-derived MDA reduced homologous virus infection, transmission, and disease,
MDA alone was sufficient to induce VAERD upon heterologous infection.
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a b s t r a c t
Control of inﬂuenza A virus (IAV) in pigs is done by vaccination of females to provide maternally-derived
antibodies (MDA) through colostrum. Our aim was to evaluate if MDA interfere with IAV infection,
clinical disease, and transmission in non-vaccinated piglets. In the ﬁrst study, naïve sows were vaccinated
with H1N2-δ1 whole inactivated virus (WIV) vaccine. In a follow-up study seropositive sows to 2009
pandemic H1N1 (H1N1pdm09) were boosted with H1N1pdm09 WIV or secondary experimental infec-
tion (EXP). MDA-positive pigs were challenged with homologous or heterologous virus, and MDA-
negative control groups were included. WIV-MDA piglets were protected from homologous infection.
However, piglets with WIV-derived MDA subsequently challenged with heterologous virus developed
vaccine associated enhanced respiratory disease (VAERD), regardless of history of natural exposure in the
sows. Our data indicates that although high titers of vaccine-derived MDA reduced homologous virus
infection, transmission, and disease, MDA alone was sufﬁcient to induce VAERD upon heterologous
infection.
Published by Elsevier Inc.
Introduction
Inﬂuenza A virus (IAV) is endemic in pigs in North America and
greatly impacts the swine industry due to health related losses. In
addition, there are public health concerns in regards to the zoo-
notic potential of swine-adapted lineages of IAV (Myers et al.,
2007). IAV evolves rapidly in pigs and many distinct strains cur-
rently co-circulate in North American swine populations. Endemic
swine viruses can be classiﬁed by their hemagglutinin (HA) gene
into different phylogenetic clusters within the H3 (IV-A, -B, -C, -D,
-E, -F) and H1 (α, β, γ, δ1, δ2 and H1N1pdm09) subtypes (Lorusso
et al., 2013; Vincent et al., 2008b). Different genetic clusters are
often antigenically distinct, and limited serological cross-reactivity
can be detected even within a cluster, such as the δ clusters (Lewis
et al., 2014; Lorusso et al., 2011; Vincent et al., 2008b). This limited
cross-reactivity represents an obstacle to efﬁcacious vaccine
development.
Vaccination of breeding females against IAV to stimulate pas-
sive antibody transfer via colostrum is a common practice in the U.
S. swine industry and is typically done using multivalent whole
inactivated virus (WIV) vaccines (Vincent et al., 2008b). In
homologous infections, in which vaccine and challenge viruses are
similar or matched, maternally-derived antibodies (MDA) acquired
via colostrum are correlated with protection of piglets from clin-
ical disease, but without a reduction of upper respiratory tract
viral shedding (Kitikoon et al., 2006; Loeffen et al., 2003). How-
ever, signiﬁcant levels of MDA were associated with inhibition of
the active IgA, IgM, IgG, and hemagglutination inhibition (HI)
responses, as well as the proliferative T-cell response upon pri-
mary or secondary exposure to the virus (Loeffen et al., 2003;
Loving et al., 2014; Loving et al., 2013; Sandbulte et al., 2014;
Vincent et al., 2012).
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Non-neutralizing, cross-reacting immunity elicited following
administration of adjuvanted, inactivated vaccines not only fails
to protect against homosubtypic heterologous viruses, but can
lead to severe bronchointerstitial pneumonia with necrotizing
bronchiolitis, a phenomenon known as vaccine-associated
enhanced respiratory disease (VAERD) (Gauger et al., 2012,
2011; Vincent et al., 2008a). Exacerbated pneumonia was repor-
ted in unvaccinated piglets with MDA from sows vaccinated with
a commercial WIV (Pyo et al., 2015). Yet, in that same study and
others (Loving et al., 2012; Vincent et al., 2007) live-attenuated
inﬂuenza virus (LAIV) vaccines induced mucosal immune
responses and provided improved cross-protection to hetero-
logous IAV challenge in pigs, even in the presence of MDA (Pyo
et al., 2015; Vincent et al., 2012), thus presenting an alternative to
improve vaccine efﬁcacy in piglets.
Though currently available commercial inactivated products do
not provide optimal protection, vaccination of dams with WIV can
be beneﬁcial in case of homologous exposure of litters, reducing
clinical signs and shedding, and is still frequently used as a control
measure against IAV infection. Here, we investigated if the pre-
sence of passive MDA at the time of heterologous challenge would
result in enhanced disease. Our study used two scenarios: one in
which seronegative sows were vaccinated with WIV as a proof of
concept and the other a scenario likely to occur in the ﬁeld in
which seropositive sows previously naturally exposed to IAV were
vaccinated with the same virus strain and their litters were chal-
lenged with the homologous or heterologous virus. Our ﬁndings
show that although high titers of vaccine-derived MDA reduced
homologous virus infection, transmission, and disease, MDA alone
was sufﬁcient to induce VAERD upon heterologous infection.
Results
Serology
Pigs in the MDA-negative groups remained seronegative
throughout the study. MDA were efﬁciently transferred from dams
to their piglets, as measured by serum HI titers and IAV-speciﬁc
IgG levels at 3 days of age (data not shown), and before and after
challenge (Fig. 1A–F). No HI cross-reactivity against heterologous
challenge viruses was detected in any of the MDA-positive groups
in Studies 1 or 2 (data not shown). However, serum IgG cross-
reactive against the heterologous virus was detected in the WIV-
derived MDA groups before and after challenge (Fig. 1E and F), but
not in any other group. All naïve pigs placed into indirect contact
with heterologous challenged pigs seroconverted by 15 days post-
contact (dpc), with geometric mean HI titers ranging from 30 to
278. None of the pigs in indirect contact with WIV-MDA pigs that
were challenged with homologous H1N1 in Study 2 seroconverted
by HI assay.
Titers of HI MDA were low in pigs from Study 3 at 13 weeks of
age and below the detection limit by 16 weeks of age, however
most of the pigs (11/14) still had detectable levels of IAV-speciﬁc
serum IgG until the day of vaccination (Fig. 2A). MDA-positive pigs
vaccinated with the sameWIV vaccine as their mothers showed no
increase in neutralizing antibody levels against the vaccine strain
or against a H1N1-γ strain (Fig. 2B and D). MDA-positive pigs
vaccinated with the commercial vaccine only had a detectable
antibody response against the swine H3N2 and H1N1-δ2 antigens
(Fig. 2C and E), components of the vaccine that do not cross-react
by HI assay with the H1N1pdm09-speciﬁc MDA, but titers were
lower than titers in the MDA-negative controls that received the
commercial vaccine.
Mucosal antibody response
Animals that suckled colostrum with MDA elicited from
boosting prior natural exposure immunity (WIV and EXP) had
signiﬁcant levels of IAV-speciﬁc IgA in nasal wash (NW) at 3 days
of age, but this was not observed for animals that suckled from
sows with MDA elicited only from prior natural exposure (NAT–
MDA; Fig. S1). Low titers of homologous neutralizing antibodies
were also detected in the nasal washes collected from 3 day-old
piglets with MDA (Fig. S1).
At 5 days postinfection (dpi), there were signiﬁcant levels of
homologous IgG in the lungs of all MDA-positive pigs (Fig. 1G and
H). No IgG cross-reactivity against the heterologous virus was
detected in pigs with WIV-MDA in Study 1 (Fig. 1G), but low cross-
reactivity was observed in Study 2, although not statistically sig-
niﬁcant (Fig. 1H). IAV-speciﬁc IgA was not detected in any of the
groups (data not shown).
Cell mediated immunity (CMI) transfer via colostrum
The transfer of IAV-speciﬁc CMI to homologous and hetero-
logous viruses through colostrum was assessed in each T-cell
subset by MP-FCM prior to challenge. Although some minor dif-
ferences were observed between different MDA status groups,
overall antigen-driven increases in the expression of CD25, IFN-γ
and IL-10 were nearly undetectable in all T-cell populations of
weaned piglets (Fig. S2). The piglets had almost no CD4þCD8þ
population, and therefore these results were not included (data
not shown). IAV-speciﬁc CMI results in sows were added to graphs
as positive values for illustration purpose.
Clinical disease
Challenge with either virus did not result in apparent clinical
signs in MDA-negative pigs or homologous MDA-positive pigs.
Pigs challenged in the presence of heterologous WIV-derived MDA
showed moderate to severe coughing, increased respiratory rate
and respiratory distress. Two pigs in the WIV-MDA/H1N2 group
(heterologous) of Study 2 showed severe coughing, lethargy, and
dyspnea, and died from respiratory disease at 2 dpi. All infected
animals showed a peak in rectal temperatures at 1 dpi when
compared to non-challenged pigs, except for pigs with homo-
logous MDA in both studies and pigs with MDA elicited from only
natural infection (Fig. S3).
Lung and trachea pathology
Naïve pigs challenged with either IAV strain had moderate lung
pathology typical of IAV infection. In Studies 1 and 2, pigs chal-
lenged with H1N1pdm09(2:6) or H1N2-δ1(1:7) in the presence of
homologous WIV-MDA had macroscopic scores similar to non-
challenged pigs (Tables 1 and 2). In contrast, the heterologous
challenged pigs developed enhanced macroscopic pneumonia,
compared to their MDA-negative counterparts (Tables 1 and 2).
Notably, there was no enhancement in macroscopic lesions in pigs
with natural or booster experimental infection-MDA that were
challenged with heterologous virus. Additionally, EXP-MDA
resulted in reduced macroscopic lung pathology following homo
logous challenge (Table 2).
Pigs with WIV-MDA had lower microscopic lesion scores after
homologous challenge when compared to the MDA-negative
challenged groups in both studies, indicating at least partial pro-
tection. The presence of WIV-derived MDA at the time of hetero-
logous challenge did not result in enhanced microscopic pneu-
monia and scores were not statistically different from the control
groups, which is in contrast to macroscopic lesions for these
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Fig. 1. Serum and lung IAV-speciﬁc antibody levels due to maternally-derived antibodies (MDA) induced by vaccinating naïve dams with H1N2-δ1(1:7) WIV (Study 1) or
boosting seropositive dams with H1N1pdm09 WIV or experimental infection (EXP) or from a non-boosted naturally exposed sow (NAT-MDA; Study 2). Reciprocal geometric
mean HI titers against the homologous vaccine antigens are shown for 0 and 5 days postinfection (dpi for Study 1 (A) and Study 2 (B). Mean optical density (O.D.) in whole-
virus ELISAs for serum IgG against H1N2-δ1 antigen (C, F) and H1N1pdm09 antigen (D, E). Mean O.D. in whole-virus ELISAs for BALF IgG against homologous and het-
erologous antigens to the vaccine in Study 1 (G) and Study 2 (H). Treatments in Study 1 (A, C, E, G) were: pigs with no MDA or H1N2-δ1(1:7) WIV-MDA, challenged with
homologous H1N2-δ1(1:7) or heterologous H1N1pdm09(2:6) virus. Treatments in Study 2 (B, D, F, H) were: pigs with no MDA, H1N1pdm09 WIV-MDA, H1N1pdm09 EXP-
MDA, or H1N1pdm09 NAT-MDA challenged with homologous H1N1pdm09(2:6) or heterologous H1N2-δ1(1:7).
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Fig. 2. Serum IAV-speciﬁc antibody levels in pigs vaccinated with H1N1pdm09 whole inactivated virus vaccine (WIV) or commercial quadrivalent vaccine (COM) in the
presence of IAV-speciﬁc maternally-derived antibodies (MDA). Pigs were vaccinated at 16 weeks of age, when MDA HI titers dropped below the limit of detection (dotted
line). (A) Reciprocal geometric mean HI titers against H1N1pdm09 antigen and mean optical density (O.D.) in inﬂuenza A virus IgG-speciﬁc ELISA at 1, 9, 13 and 16 weeks of
age; reciprocal geometric mean HI titers at 0, 14 and 28 days postvaccination against H1N1pdm09 (B), H3N2-IV (C), H1N1-γ (D), and H1N1-δ2 (E) antigens. Asterisks indicate
signiﬁcant difference between MDA-statuses within the same vaccine (Pr0.05).
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groups (Tables 1 and 2). WIV-MDA pigs with macroscopic evi-
dence of VAERD demonstrated less peribronchiolar lymphocytic
cufﬁng and interstitial pneumonia compared to our traditional
WIV VAERD model, although necrotizing bronchiolitis typical of
inﬂuenza infection was apparent (Gauger et al., 2012). Pigs that
suckled from an H1N1pdm09 naturally exposed sow that was not
boosted showed higher microscopic pneumonia scores than MDA-
negative infected counterparts (Table 2).
Virus levels in lung and nasal secretions
Virus was not detected in NC pigs at any time throughout the
studies, or in the nasal swabs (NS) of any pigs on the day of
challenge. Pigs with H1N2-δ1 WIV-MDA challenged with homo-
logous virus in Study 1 showed lower virus titers in nasal secre-
tions when compared with the MDA-negative infected controls
(Table 3), although virus transmitted to naïve, indirect contact pigs
(Fig. 3A). Similarly, H1N1pdm09-MDA elicited from WIV or sec-
ondary experimental infection provided effective protection
against the nasal shedding of homologous virus in Study 2, as
limited virus was detected in NS collected from these treatment
groups on any dpi (Table 4). Notably, only one WIV-MDA/H1N1 pig
shed virus after challenge and none of the pigs in indirect contact
with this group shed virus (Fig. 3B). However, pigs in the EXP-
MDA/H1N1 indirect contact group became infected (Fig. 3B). In
contrast, neither H1N1pdm09 nor H1N2-δ1 MDA protected
against shedding of heterologous challenge virus, as there was no
difference in titers from MDA-negative infected controls on dpi 1–
4 (Tables 3 and 4), and all pigs in indirect contact became infected
(Fig. 3A and B). By 5 dpi, MDA elicited from H1N1pdm09-WIV
vaccination resulted in signiﬁcantly lower nasal viral shedding
from pigs challenged with heterologous H1N2-δ1 in Study 1
(Table 4).
Consistent with the reduced viral shedding, MDA against
H1N1pdm09 provided protection against homologous virus replica-
tion in the lungs, as no virus was detected in the lungs of WIV-MDA/
H1N1 pigs at 5 dpi in Study 2 (Table 4), but the samewas not observed
forWIV-MDA pigs after homologous challengewith H1N2-δ1 in Study
1 (Table 3). H1N1pdm09 virus titers in the lungs of control pigs
without MDA were different between studies, even though inoculum
back titrations were similar (data not shown), with titers in Study
1 lower than in Study 2 (Tables 3 and 4).
Cytokine concentrations in bronchoalveolar lavage ﬂuid (BALF)
were evaluated at 5 dpi in Studies 1 and 2, and different patterns
were observed between the two studies. Overall, pigs in Study
2 showed higher levels of all cytokines when compared to Study 1
(Fig. S4); however, the pattern of distinct cytokine dysregulation
seen in our previous VAERD studies (Gauger et al., 2012; Gauger et
al., 2011) was not observed.
Discussion
Currently, protection of pigs against IAV relies primarily on the
use of inactivated vaccines, most commonly in breeding females
(Vincent et al., 2008b). Sows vaccinated prior to farrowing often
have high HI antibody titers against vaccine virus(es) that may
lead to long-lasting maternally-derived anti-IAV antibodies in
piglets (Markowska-Daniel et al., 2011). MDA has been shown to
protect piglets against clinical disease with homologous infection
(Choi et al., 2004; Kitikoon et al., 2006; Loeffen et al., 2003), but
the level of protection may be greatly inﬂuenced by the virus
strain, the levels of MDA and the age at the time of infection
(Loeffen et al., 2003). Additionally, the expanded genetic diversity
of IAV in swine in the U.S. over the past two decades has led to the
co-circulation of numerous genetic and antigenic virus strains
(Lorusso et al., 2013; Olsen, 2002; Vincent et al., 2008b), making it
difﬁcult to rely on vaccine-derived MDA to cross-protect nursery
pigs against heterologous viruses. Here, we demonstrated different
outcomes following IAV challenge of piglets depending on the
method used to elicit IAV-speciﬁc MDA and the challenge virus
used (homologous versus heterologous to MDA). While WIV-
induced MDA provided better protection than natural exposure
and boosted-exposure MDA against homologous challenge, WIV-
induced MDA were also associated with enhanced clinical signs
when pigs were exposed to a heterologous H1 virus, irrespective
to the previous serological status of the sows.
The epitheliochorial placenta of sows does not allow for the
transfer of immunoglobulin from sow to piglets in utero;
Table 1
Mean percentage macroscopic pneumonia, composite microscopic pneumonia, and
trachea microscopic scores7standard error of the mean (SEM) for groups with
maternally-derived antibodies (MDA) from sows vaccinated with H1N2-δ1(1:7)
whole inactivated virus vaccine (WIV-MDA) or without MDA (No MDA) at 5 days
post infection (dpi) with homologous H1N2-δ1(1:7) or heterologous H1N1pdm09
(2:6) in Study 1.
Challenge
groups
Macroscopic per-
centage (%)
Microscopic
scores (0–22)
Trachea histopathol-
ogy (0–8)
Homologous
No MDA/NC 0.070.0a 0.670.2a 0.070.0a
No MDA/
H1N2
13.472.6b 7.270.7b 1.570.4b
WIV-MDA/
H1N2
2.871.1a 1.570.5a 1.170.4a,b
Heterologous
No MDA/NC 0.070.0a 0.670.2a 0.070.0a
No MDA/
H1N1
16.872.3b 10.670.9b 1.070.2a,b
WIV-MDA/
H1N1
24.772.1c 9.870.6b 2.070.4b
a,b,c Statistically signiﬁcant differences identiﬁed with different lowercase let-
ters (Pr0.05).
Table 2
Mean percentage macroscopic pneumonia, composite microscopic pneumonia, and
trachea microscopic scores7standard error of the mean (SEM) from pigs with
maternally-derived antibodies (MDA) from exposed sows vaccinated with
H1N1pdm09 whole inactivated virus (WIV-MDA) vaccine or experimentally
infected with H1N1pdm09 (EXP-MDA), or from a non-boosted naturally exposed
sow (NAT-MDA), or without MDA (No MDA) at 5 days post infection (dpi) with
homologous H1N1pdm09(2:6) or heterologous H1N2-δ1(1:7) in Study 2.
Challenge
groups
Macroscopic per-
centage (%)
Microscopic
scores (0–22)
Trachea histopathol-
ogy (0–8)
Homologous
No MDA/NC 0.470.1a 1.370.1a 0.170.1a
No MDA/
H1N1
24.672.3b 15.270.6b 1.770.3b,c
WIV-MDA/
H1N1
0.770.4a,c 5.370.1c 0.870.6a,b
EXP-MDA/
H1N1
8.271.8c 10.470.9d 2.470.2c
Heterologous
No MDA/NC 0.470.1a 1.370.1a 0.170.1a
No MDA/
H1N2
15.272.0b 13.470.7b 3.170.5b
WIV-MDA/
H1N2
28.978.1c 13.471.0b 3.070.6b
EXP-MDA/
H1N2
17.672.0b,c 12.070.8b 2.370.4b
NAT-MDA/
H1N2
16.272.9b 17.771.1c 3.570.6b
a,b,c Statistically signiﬁcant differences in the same column identiﬁed with
different lowercase letters (Pr0.05).
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therefore, pigs are born agammaglobulinemic (Sterzl et al., 1966).
Hence, newborn swine depend on the ingestion of colostrum to
passively acquire antibodies (referred to as maternally-derived
antibody, MDA) as a ﬁrst line of defense against pathogens in the
ﬁrst weeks of life. In this study, IAV-speciﬁc antibodies were suc-
cessfully transferred to the litters of vaccinated or naturally/
experimentally infected sows, as all pigs that suckled from these
sows had detectable levels of serum HI and IgG antibodies against
the immunizing strains prior to challenge. Previous studies have
shown that maternally-derived lymphoid cells are also absorbed
from the digestive tract of piglets after colostrum ingestion, and
transported to peripheral blood and various tissues, such as liver,
lungs, lymph nodes, spleen and gastrointestinal tract (Tuboly and
Bernath, 2002; Williams, 1993). However, we did not detect an
IAV-speciﬁc IFN-γ and IL-10 recall response in peripheral T cells
from 3 weeks-old piglets that suckled colostrum from vaccinated
sows (Fig. S2). Both antigen-speciﬁc IgG and monomeric IgA have
been shown to transudate into the lungs (presumably from the
periphery) of piglets after colostrum ingestion, with levels peaking
at 3 days after birth (Nechvatalova et al., 2011). We were able to
detect signiﬁcant levels of anti-H1N1pdm09 IgA in the nasal cavity
of MDA-positive piglets at 3 days of age, but levels dropped bellow
the detection limit by 3 weeks of age (data not shown). The pre-
sence of maternally-derived IgA in the nasal wash of newborn
piglets must be interpreted with caution, as this could be a result
of aspiration or spill during colostrum feeding.
Homologous IAV-speciﬁc MDA typically protects piglets against
disease but often does not prevent infection or reduce viral
shedding (Choi et al., 2004; Kitikoon et al., 2006; Loeffen et al.,
2003). A previous study showed that pigs challenged in the pre-
sence of homologous MDA shed virus for a longer period of time,
and these pigs had an inhibition or delay in induction of an active
antibody and cellular immune response (Loeffen et al., 2003).
Here, challenge with either H1N1pdm09 or H1N2-δ1 resulted in
no apparent clinical signs in pigs with homologous MDA, and
reduced lung and trachea lesions (Tables 2 and 3). Notably, mat-
ched MDA elicited from WIV administration in sows previously
exposed to IAV also protected piglets from homologous infection
and prevented transmission, as only one principal pig in this group
shed low titers of virus after challenge, and there was no trans-
mission to indirect naïve contact pigs. Secondary experimental
infection of seropositive sows also resulted in transfer of immunity
that provided protection of their litters from development of
clinical disease following homologous challenge, but there was no
protection against infection or transmission. This was likely due to
the lower levels of IAV-speciﬁc peripheral antibodies in the sows
that resulted in lower levels transferred to their piglets.
The presence of WIV-derived MDA led to a very different out-
come when pigs were challenged with a virus heterologous to the
vaccine strain, regardless of the sows being previously exposed or
not. The WIV-MDA not only failed to protect the piglets against
infection and disease, it resulted in enhanced clinical signs and
pathology associated with VAERD (Gauger et al., 2012), albeit at an
intermediate level of enhancement only apparent for macroscopic
pathology, as VAERD-affected piglets demonstrated similar mean
microscopic lung lesion scores compared to the no-MDA chal-
lenged control groups. Notably, when previously exposed sows
were boosted with WIV vaccine, the resulting disease enhance-
ment in their piglets seemed more pronounced, and two piglets
succumbed at 2 dpi with severe respiratory disease. In both stu-
dies, WIV-induced MDA was shown to cross-react with the het-
erologous virus by whole virus ELISA (Fig. 1), a parameter
Table 3
Virus titers in nasal swabs at 1 to 5 days post infection (dpi) and bronchoalveolar lavage ﬂuid (BALF) at 5 dpi from pigs with maternally-derived antibodies (MDA) from sows
vaccinated with H1N2-δ1(1:7) WIV or without MDA and challenged with homologous H1N2-δ1(1:7) or heterologous H1N1pdm09(2:6) in Study 1. Values shown as
mean7standard error of the mean (SEM).
Challenge groups Nasal swabsa BALFa
1 dpi 2 dpi 3 dpi 4 dpi 5 dpi 5 dpi
No MDA/NC 0.070.0b 0.070.0b 0.070.0b 0.070.0b 0.070.0b 0.070.0b
Homologous
No MDA/H1N2 1.570.4c 1.970.4c 2.370.4c 2.870.3c 2.870.2c 3.970.5c
WIV-MDA/H1N2 0.070.0b 0.170.1b 0.870.4b 0.870.4b 0.170.1b 2.770.7c
Heterologous
No MDA/H1N1 1.270.2c 1.070.1c 1.070.1b,c 1.570.2c 1.070.2c 0.770.4b
WIV-MDA/H1N1 1.370.3c 0.570.2b,c 1.470.2c 1.270.2c 1.070.2c 1.370.4b
a Virus titers represented as log10 TCID50/ml.
b,c,d Statistically signiﬁcant differences within same challenge virus groups in the same column identiﬁed with different lowercase letters (Pr0.05).
Fig. 3. Mean virus titers in nasal swabs of naïve sentinel pigs at 1 to 5, 7, 9, and 11
days post indirect contact (dpc) with pigs with maternally-derived antibodies
(MDA) challenged with homologous or heterologous virus. Treatments in Study 1
(A) were: pigs with no MDA and with MDA from vaccination of naïve sows with
H1N2-δ1(1:7) WIV, challenged with homologous H1N2-δ1(1:7) or heterologous
H1N1pdm09(2:6). Treatments in Study 2 (B) were: pigs with no MDA, and with
MDA from H1N1pdm09 WIV vaccination of seropositive sows, from experimental
infection of seropositive sows with H1N1pdm09 (EXP-MDA), or from a non-boos-
ted H1N1pdm09 naturally exposed sow (NAT-MDA) challenged with homologous
H1N1pdm09(2:6) or heterologous H1N2-δ1(1:7). The dotted line indicates the
assay's limit of detection.
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frequently observed in VAERD (Gauger et al., 2012, 2011; Rajao et
al., 2014). Antibody-dependent enhancement (ADE) or antibody
mediated complement ﬁxation may play an important role in the
enhanced pathology associated with VAERD, in which the pre-
sence of non-protective antibodies and antigen–antibody com-
plexes could lead to increased virus uptake, enhanced replication,
and dysregulated inﬂammation (Huisman et al., 2009). Remark-
ably, even though MDA induced through natural IAV exposure
without boosting did not protect piglets against heterologous
challenge with H1N2-δ1, it did not result in VAERD. The same was
observed in piglets with MDA elicited after boosting sows with
secondary IAV exposure, which did not seem to increase the levels
of IAV-speciﬁc IgG transferred via colostrum (Fig. 1), consistent
with the transfer of lower antibodies levels mentioned above. The
implication that antibodies are the immune component driving
VAERD is consistent with the report that cross-reacting, non-
neutralizing serum IgG directed towards the HA conserved stalk
domain increased acute infection by enhancing virus fusion in vitro
(Khurana et al., 2013). Importantly, the lack of maternally-derived
IAV-speciﬁc CMI at the time of challenge suggests that antibodies
alone may trigger the inciting events leading to VAERD. However,
IAV-speciﬁc CMI responses likely are involved in the severity of the
enhancement, as evidenced here by the microscopic lesions with
less leukocyte recruitment and reduced cytokine responses com-
pared to the traditional VAERD model (Gauger et al., 2011).
In addition to the limited protection and risk of enhanced
respiratory disease, previous studies have shown MDA inter-
ference on the immune response to vaccination in piglets (Kiti-
koon et al., 2006; Markowska-Daniel et al., 2011; Sandbulte et al.,
2014; Vincent et al., 2012). In herds that routinely vaccinate
breeding females during gestation, high titers of MDA can be
detected by HI in offspring until 14 weeks of age (Markowska-
Daniel et al., 2011), thus, vaccination of weaned pigs may be
negatively impacted. Here, MDA elicited from WIV-boosting of
naturally exposed sows capable of neutralizing homologous virus
were detected until 13 weeks of age, but NP-speciﬁc antibodies
were still detected at 16 weeks of age. Notably, although homo-
logous HI antibody titers were low or undetectable at the time of
vaccination of these pigs, the interference with vaccine-induced
immunity was still evident. Commercial multivalent vaccines
induced no HI response against strains similar to that of the MDA,
and there were reduced responses to other distant strains in the
vaccine (Fig. 2). Similar results were observed previously when
pigs were vaccinated at various ages in the presence of MDA: a
higher antibody response was observed if pigs were older at the
time of ﬁrst vaccination, and the response was dependent on
weaning of MDA levels (Markowska-Daniel et al., 2011).
Our data show that high titers of homologous vaccine-elicited
MDA can reduce infection, transmission, and/or disease following
homologous exposure. Importantly, MDA alone made piglets sus-
ceptible to VAERD upon heterologous infection. Swine IAV diver-
sity has increased rapidly, at a pace that current control strategies,
such as WIV vaccination, are not able to follow. Beside the
potential for failure of protection from WIV or WIV-elicited MDA
against antigenically distant viruses, there is a practical risk for
VAERD to occur in the ﬁeld. Thus, the selection of WIV vaccine, the
timing of vaccination in sows, and immune status are crucial to
assure adequate MDA coverage. In addition, the use of diagnostic
and surveillance data to monitor genetic and antigenic evolution
of viruses circulating in swine populations, along with improved
methodologies for evaluation of vaccine responses, are needed to
develop more effective intervention strategies against this
important pathogen.
Material and methods
Vaccines and viruses
The antigen for the WIV vaccine in Study 1 was obtained via
reverse genetics and contained the HA from A/swine/Minnesota/
02011/08 H1N2 δ1 (H1N2-δ1) and the other seven genes from A/
turkey/Ohio/313053/2004 H3N2 (here on referred to as H1N2-δ1
(1:7)). The H1N1pdm09 antigen used for the WIV vaccine and
booster exposure in Studies 2 and 3 was A/New York/18/2009
H1N1. The WIV vaccines were generated by UV inactivation of the
viruses, using the “sterilize” setting in a UV cross-linking chamber
(GS Gene Linker; Bio-Rad, Hercules, CA). A commercial oil-in-
water adjuvant (Emulsigen D, MVP Laboratories, Inc., Ralston, NE)
was added at a 1:5 ratio (v/v), and each dose of WIV contained
approximately 64 hemagglutination (HA) units. Viruses used for
challenge were the H1N2-δ1(1:7) and another reverse genetic-
generated virus containing the surface genes from the
H1N1pdm09 A/California/04/2009 and the other six genes from A/
turkey/Ohio/313053/2004 H3N2 (here on referred to as
H1N1pdm09(2:6)). Vaccine and challenge viruses were grown in
Madin-Darby canine kidney (MDCK) cells or embryonated
chicken eggs.
Table 4
Virus titers in nasal swabs at 1 to 5 dpi and bronchoalveolar lavage ﬂuid (BALF) at 5 dpi from pigs with maternally-derived antibodies (MDA) from exposed sows vaccinated
with H1N1pdm09 whole inactivated virus (WIV-MDA) vaccine or experimentally infected with H1N1pdm09 (EXP-MDA), or from a non-boosted H1N1pdm09 naturally
exposed sow (NAT-MDA), and without MDA (No MDA) at 1 to 5 days post infection (dpi) with homologous H1N1pdm09(2:6) or heterologous H1N2-δ1(1:7) in Study 2.
Values shown as mean7standard error of the mean (SEM).
Challenge groups Nasal swabsa BALFa
1 dpi 2 dpi 3 dpi 4 dpi 5 dpi 5 dpi
No MDA/NC 0.070.0b 0.070.0b 0.070.0b 0.070.0b 0.070.0b 0.070.0b
Homologous
No MDA/H1N1 1.270.3c 1.170.2c 1.770.2c 2.370.2c 1.070.2c 4.270.3c
WIV-MDA/H1N1 0.070.0b 0.170.1b 0.070.0b 0.170.1b 0.170.1b 0.070.0b
EXP-MDA/H1N1 0.070.0b 0.670.3b,c 0.670.4b 0.770.3b 0.470.1b,c 3.770.6c
Heterologous
No MDA/H1N2 2.870.3c 2.670.2c 3.370.3c 3.170.2c 3.070.2c 5.170.3c
WIV-MDA/H1N2 2.570.6c 2.170.4c 3.070.3c 2.970.2c 1.670.4d 6.070.2c,d
EXP-MDA/H1N2 2.870.4c 2.670.5c 3.070.2c 2.770.3c 2.870.4c 6.870.2d
NAT-MDA /H1N2 1.170.5d 3.170.4c 2.370.4c 2.870.1c 2.570.4c,d 6.170.2c,d
a Virus titers represented as log10 TCID50/ml.
b,c,d Statistically signiﬁcant differences within same challenge virus group in the same column identiﬁed with different lowercase letters (Pr0.05).
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In vivo Study 1
To investigate if the presence of MDA would result in enhanced
disease after heterologous infection, we challenged piglets
obtained from WIV vaccinated sows. Four naive sows were
obtained from a high-health status herd free of porcine repro-
ductive and respiratory syndrome virus (PRRSV) and IAV. Sows
were shown to be free of anti-IAV antibodies prior to the start of
the study, and were vaccinated intramuscularly with 2 ml of the
H1N2-δ1(1:7) WIV. Each sow received 3 doses: 2 weeks prior to
breeding; 6 and 4 weeks prior to farrowing. All sows delivered
their litters without intervention, and piglets suckled their
own dams.
Piglets were bled at 3 days of age for evaluation of IAV-speciﬁc
MDA transfer by HI assay, and they were weaned at approximately
2 weeks of age. Forty-ﬁve two-week-old cross-bred healthy pigs
from serologically negative dams were obtained from the same
source herd to be used as controls and naïve contacts without IAV-
speciﬁc MDA. All pigs were treated with ceftiofur crystalline-free
acid (Excedes, Zoetis, Florham Park, NJ) and enroﬂoxacin (Bay-
trils, Bayer Animal Health, Shawnee Mission, KS) at weaning or
arrival to reduce respiratory bacterial contaminants. Pigs were free
of IAV by nasal swab sampling, and MDA-negative controls were
free of IAV-antibodies prior to start of the study. Pigs were housed
in biosafety level 2 (BSL2) containment and cared for in com-
pliance with the Institutional Animal Care and Use Committee of
the National Animal Disease Center. At weaning, 20 pigs with MDA
and 20 pigs without MDA were divided into 4 groups (Table 5).
Four pigs with and 5 pigs without MDAwere combined into a non-
challenged control (NC) group.
At 3 weeks-of-age, pigs in each challenge group (principal pigs)
were inoculated simultaneously with 2 ml intratracheal and 1 ml
intranasal 1105 50% tissue culture infective dose (TCID50) per ml
of the indicated challenge virus (Table 5). Inoculation was per-
formed under anesthesia following an intramuscular injection of a
cocktail of xylazine (4 mg/kg), ketamine (8 mg/kg of body weight),
and Telazol (6 mg/kg) (Zoetis Animal Health, Florham Park, NJ).
Two dpi, 20 MDA-negative pigs (n¼5 per group) were placed in
separate raised decks in the same room as each inoculated group,
to evaluate indirect contact transmission. Principal pigs were
observed daily for clinical signs of respiratory disease and rectal
temperatures were measured at 0 to 5 dpi. Principal pigs were
humanely euthanized with a lethal dose of pentobarbital (Fatal
Pluss, Vortech Pharmaceuticals, Dearborn, MI) and necropsied at
5 dpi, when BALF, trachea and right cardiac or affected lung lobe
were collected. Indirect contact pigs were bled and humanely
euthanized at 15 dpc.
In vivo Study 2
In a follow-up study, to mimic a scenario likely to occur in the
ﬁeld, seropositive sows were boosted with a homologous virus
strain and their piglets were challenged with homologous or
heterologous virus. Six sows with IAV-speciﬁc antibodies elicited
from previous natural exposure to H1N1pdm09 were subse-
quently boosted with WIV or additional exposure to wild-type
virus to evaluate the differential effect of passive maternal anti-
body derived from WIV vaccination versus natural exposure on
IAV infection in piglets. Sows were either vaccinated intramuscu-
larly with 2 ml of H1N1pdm09 WIV (n¼3) or infected intranasally
with 2 ml of 1106 TCID50/ml of the virus used in the WIV (n¼2).
Each sow was boosted using the same vaccine regimen as in Study
1. The remaining sow was not vaccinated or infected to derive
piglets that would serve as controls. All sows delivered their litters
without intervention, and piglets suckled their own dams.
Forty-ﬁve, two-week-old cross-bred, healthy pigs were
obtained from the same source as in Study 1 and used as naïve
controls and contacts without IAV-speciﬁc MDA. All piglets were
evaluated, treated and cared for in the same manner as described
for Study 1. At weaning, 40 pigs with MDA were divided into
5 groups and 16 pigs without MDA were divided into 2 groups
(Table 5). Three pigs from each MDA status were combined into a
non-challenged (NC) control group. Piglets with MDA from the
non-boosted sow (NAT-MDA) were used to test if MDA elicited by
prior natural exposure would have the same effect on IAV infection
as MDA transferred after boosting the sows’ IAV-speciﬁc immu-
nity. Principal pigs were challenged with H1N2-δ1(1:7) or
H1N1pdm09(2:6) as shown in Table 5. Indirect naïve contacts
were placed with each inoculated group as described above,
except in the NAT-MDA/H1N2 group. Challenge, sampling and
necropsies were performed as described above for Study 1.
In vivo Study 3
Fourteen piglets born to the H1N1pdm09-WIV boosted sows
from Study 2 were used to evaluate long-term MDA interference
on WIV vaccination of weaned pigs (Table 5). When the piglets' HI
antibody titers dropped below the positive cutoff reciprocal titer of
40, pigs were vaccinated with either the same adjuvanted
H1N1pdm09 WIV vaccine as their dams (n¼7) or with a com-
mercial quadrivalent inﬂuenza vaccine (n¼7) containing H1N1-γ,
H1N2-δ1, H1N1-δ2 and H3N2-IV cluster viruses (Flusures XP,
Zoetis Animal Health, Florham Park, NJ) following the manu-
facturer’s recommendations. Four naïve pigs obtained from the
Table 5
Experimental design and group assignments for all three studies.
Treatment
group
Source of MDA Challenge strain or
vaccine typea
N Indirect con-
tacts (N)
Study 1
No MDA/NC None None 9 –
No MDA/H1N2 None H1N2-δ1(1:7)b 10 5
WIV-MDA/
H1N2
WIV H1N2-δ1(1:7) 10 5
No MDA/H1N1 None H1N1pdm09(2:6)b 10 5
WIV-MDA/
H1N1
WIV H1N1pdm09(2:6) 10 5
Study 2
No MDA/NC None None 9 –
No MDA/H1N1 None H1N1pdm09(2:6) 8 5
WIV-MDA/
H1N1
WIV H1N1pdm09(2:6) 8 5
EXP-MDA/
H1N1
Experimental
infectiona
H1N1pdm09(2:6) 8 5
No MDA/H1N2 None H1N2-δ1(1:7) 8 5
WIV-MDA/
H1N2
WIV H1N2-δ1(1:7) 8 5
EXP-MDA/
H1N2
Experimental
infectionc
H1N2-δ1(1:7) 8 5
NAT-MDA/
H1N2
Natural infectionc H1N2-δ1(1:7) 8 –
Study 3
No MDA/WIV None WIV 2 –
WIV-MDA/WIV WIV WIV 7 –
No MDA/COM None Commercial 2 –
WIV-MDA/
COM
WIV Commercial 7 –
a Challenge strains for Studies 1 and 2, vaccine type for Study 3.
b H1N2-δ1(1:7)¼virus containing HA from A/swine/Minnesota/02011/08 H1N2
δ1 and the other seven genes from A/turkey/Ohio/313053/04 H3N2; H1N1pdm09
(2:6)¼virus containing the surface genes from A/California/04/2009 H1N1 and the
other six genes from A/turkey/Ohio/313053/04 H3N2.
c EXP-MDA pigs suckled sows which were previously naturally exposed and
then experimentally boosted with live exposure to H1N1pdm09 and NAT-MDA pigs
suckled sows which were previously naturally exposed to H1N1pdm09 only.
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same source herd as the other studies were used as controls (n¼2
per vaccine group). Vaccination was performed using 2 doses
2 weeks apart (at 16 and 18 weeks of age), and pigs were huma-
nely euthanized at 28 days post-vaccination (dpv; at 20 weeks
of age).
IAV antibody detection
To evaluate peripheral IAV-speciﬁc antibodies, serum samples
were collected by venipuncture before weaning (3 days of age),
before challenge (0 dpi), and at necropsy (5 dpi/15 dpc) in Studies
1 and 2. Serum was collected at 1, 9, 13, and 16 (pre-vaccination)
weeks of age, and at 14 and 28 dpv in Study 3. To measure the
transfer of antigen-speciﬁc local antibodies through colostrum,
NW were taken in Study 2 at 3 days of age and 0 dpi by ﬂushing
3 ml of phosphate-buffered saline (PBS) into the nostrils and col-
lecting the efﬂuent.
To check for the transfer of MDA and to check for weaning of
MDA in Study 3, an ELISA kit was used to detect anti-IAV nucleo-
protein (NP) antibodies in serum (AI MultiS-Screen Ab Test, IDEXX,
Westbrook, ME), according to the manufacturer’s recommenda-
tion. Results were measured as presence or absence of antibodies
based on the sample to negative (S/N) ratio, and means of each
treatment group were used for comparison.
For use in the HI assay, sera were heat-inactivated at 56 °C for
30 min, treated with a 20% suspension of kaolin (Sigma-Aldrich, St.
Louis, MO) followed by adsorption with 0.5% turkey red blood cells
(RBCs). HI assays were performed with H1N2-δ1 and H1N1pdm09
antigens for Studies 1 and 2, and with H1N1pdm09, an H1N1-γ (A/
Swine/Ohio/511445/2007), an H1N1-δ2 (A/Swine/Illinois/00685/
2005), and an H3N2-IV (A/Swine/Minnesota/01146/2006) for
Study 3 according to standard techniques (Kitikoon et al., 2014).
Antibody titers were reported as geometric means.
Enzyme-linked immunosorbent assays (ELISA) were performed
as previously described (Vincent et al., 2012) to evaluate the levels
of total isotype speciﬁc antibodies against H1N2-δ1(1:7) and
H1N1pdm09(2:6) in serum, NW, and BALF. Brieﬂy, Immulux-HB™
96-well plates (Dynex, Bustehrad, Czech Republic) were coated
with concentrated H1N2-δ1(1:7) or H1N1pdm09(2:6) diluted to
100 HA units/50 μl/well. Anti-swine IgG (Kirkegaard and Perry,
Gaithersburg, MD) and anti-swine IgA (Bethyl Laboratories, Mon-
tgomery, TX) were used for the assays. Serum samples were
diluted to 1:2,000. BALF and NW samples were treated with
10 mM Dithiothreitol (DTT; Sigma-Aldrich, St. Louis, MO) and
diluted to 1:4. The optical density (O.D.) was measured at 405 nm
wavelength with an automated ELISA reader. Antibody levels were
reported as the mean O.D. of duplicate wells for each sample, and
means of each treatment group were compared for each antibody
isotype (IgA or IgG).
For the neutralization assay, NW were treated with 10 mM DTT
at an initial dilution of 1:2. Samples were then two-fold serially
diluted in serum-free MEM supplemented with tosylsulfonyl
phenylalanyl chloromethyl ketone (TPCK)-trypsin and antibiotics
in 96-well plates. Neutralization assays were performed with both
challenge viruses as previously described (Gauger and Vincent,
2014). NW titers were reported as the geometric mean.
Multi-parameter ﬂow cytometry (MP-FCM)
Whole blood samples were collected from all piglets and sows
in vacutainer cell preparation tubes with sodium citrate (CPT™, BD
Diagnostics, Franklin Lakes, NJ) before challenge (0 dpi). Peripheral
blood mononuclear cells (PBMC) were isolated and tested for
activation markers by MP-FCM after in vitro stimulation with both
challenge viruses, using a previously described method (Platt et al.,
2011). Brieﬂy, PBMC of each pig were incubated with either RPMI
1640 media (Mediatech, Inc., Herndon, VA) as non-antigen sti-
mulation control, ConA at 5 μg/ml as mitogen control, undiluted
conditioned media from uninfected MDCK culture as mock-
stimulation control, or one of the challenge viruses (H1N2-δ1
(1:7) or H1N1pdm09(2:6)) as recall antigens in duplicate. Mono-
clonal primary antibodies for surface antigens CD4 (IgG2b, clone
74-12-4,VMRD, Inc., Pullman, WA), CD8α (IgG2a, clone 76-2-11,
VMRD, Inc., Pullman, WA), γδ TCR (Rat IgG2a, cat# 551543, BD
Pharmingen, San Diego, CA), CD25 (IgG1, clone PGBL25A,VMRD,
Inc., Pullman, WA), and for intracellular antigens IFN-γ (polyclonal
antibody, cat# ASC4032, Invitrogen, Carlsbud, CA) and IL-10 (IgG1,
cat# ASC9109, Invitrogen, Carlsbud, CA) were used with corre-
sponding ﬂuorochrome-conjugated secondary antibodies. Four T
cell subsets (CD4 single positive, CD4; CD8 single positive, CD8;
CD4:CD8 double positive, CD4þCD8; and γδ TCR positive, γδ)
were analyzed for the IAV-speciﬁc response of activation markers
CD25, IFN-γ and IL-10 expression. The net percentage increase of
each marker was calculated by subtracting the increase of marker-
positive cell percentage of mock-stimulated samples from the
increase of virus-stimulated samples of the same subset for the
same pig. Net negative results were adjusted to 0 before statistical
analysis.
Viral replication and shedding
Nasal swabs (NS; Nylon Minitip Flocked Dry Swabs, Copan
Diagnostics, Murrieta, CA) were taken from principal pigs daily
from 0 to 5 dpi and from indirect contact pigs on 0 to 5, 7, 9, and
11 dpc to evaluate viral shedding as previously described (Gauger
et al., 2011). NS specimens were ﬁltered (0.45 mm) and plated
onto conﬂuent phosphate-buffered saline (PBS)-washed MDCK
cells in 24-well plates for virus isolation, as previously described
(Vincent et al., 2012). For viral titration, virus isolation-positive NS
and BALF samples were 10-fold serially diluted in serum-free MEM
supplemented with 1 μg/ml TPCK-trypsin and antibiotics, and
plated onto conﬂuent MDCK cells in 96-well plates in triplicate as
previously described (Vincent et al., 2012). Cells were ﬁxed and
plates were stained for IAV nucleoprotein after 48 h incubation as
previously described (Gauger and Vincent, 2014). The TCID50/ml
virus titers were calculated for each sample by the Reed and
Muench method (Reed and Muench, 1938).
Pathological examination of the trachea and lungs
At necropsy, lungs were evaluated for the percentage of the
lung affected with lesions typical of IAV infection and a percentage
of the lung affected surface was calculated based on weighted
proportions of each lobe to the total lung volume (Halbur et al.,
1995). For histopathologic examination, trachea and lung tissue
samples ﬁxed in 10% buffered formalin were routinely processed
and stained with hematoxylin and eosin. Microscopic lesions were
evaluated and scored by a veterinary pathologist blinded to
treatment groups following previously described parameters
(Gauger et al., 2012). Individual scores were summed to give
composite scores for lung and trachea microscopic lesions. Inﬂu-
enza A virus-speciﬁc NP antigen was detected in lung and trachea
using an immunohistochemical (IHC) method and slides were
scored as previously described (Gauger et al., 2012).
Cytokine assays
Cytokine levels in cell-free lung lavage were determined using
a multiplex ELISA according to manufacturer's recommendations
(SearchLight; Aushon Biosystems, Billerica, MA). Samples were
analyzed in duplicate and results were averaged. Data is reported
as the mean levels7SEM for pigs in each treatment group.
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Statistical analysis
Mean macroscopic lesions, composite microscopic lung and
trachea scores, O.D. for ELISAs, log10-transformed virus titers, log2
transformations of HI and neutralization reciprocal titers were
analyzed using analysis of variance (ANOVA), with Pr0.05 con-
sidered signiﬁcant (Prism software; GraphPad, La Jolla, CA). Vari-
ables with signiﬁcant effects were subjected to pairwise mean
comparisons using the Tukey–Kramer test.
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